ebomi
Colour theme
Sign in
Insider · CIK 0001413350

Venkatesan Jay

CIK 0001413350 Name as filed on the most recent filing

Filed as Venkatesan Jay (17)

22 transaction lines · from 17 filings · filed 2007-10-17 to 2026-06-22 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

18 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-05-22 P, Open-market purchase Serina Therapeutics, Inc.SER 1,048, acquired Open Form 4 filing 0001413350-26-000004
2022-05-25 P, Open-market purchase Angion Biomedica Corp.ANGN 14,103, acquired Open Form 4 filing 0001601485-22-000043
2022-05-24 P, Open-market purchase Angion Biomedica Corp.ANGN 39,928, acquired Open Form 4 filing 0001601485-22-000039
2022-05-20 P, Open-market purchase Angion Biomedica Corp.ANGN 61,500, acquired Open Form 4 filing 0001601485-22-000039
2021-12-28 P, Open-market purchase Angion Biomedica Corp.ANGN 559,854, acquired Open Form 4 filing 0001601485-21-000095
2021-12-27 P, Open-market purchase Angion Biomedica Corp.ANGN 170,519, acquired Open Form 4 filing 0001601485-21-000095
2021-12-20 P, Open-market purchase Angion Biomedica Corp.ANGN 8,976, acquired Open Form 4 filing 0001601485-21-000093
2021-12-17 P, Open-market purchase Angion Biomedica Corp.ANGN 34,958, acquired Open Form 4 filing 0001601485-21-000089
2021-12-16 P, Open-market purchase Angion Biomedica Corp.ANGN 70,993, acquired Open Form 4 filing 0001601485-21-000089
2021-12-15 P, Open-market purchase Angion Biomedica Corp.ANGN 186,956, acquired Open Form 4 filing 0001601485-21-000087
2021-09-17 S, Open-market sale Alpine Immune Sciences, Inc.ALPN 3,760,000, disposed Open Form 4 filing 0001626199-21-000113
2021-02-09 S, Open-market sale Angion Biomedica Corp.ANGN 2,546,832, disposed Open Form 4 filing 0001601485-22-000045
2021-02-09 S, Open-market sale Angion Biomedica Corp.ANGN 2,546,832, disposed Open Form 4 filing 0001567619-21-003193
2019-08-02 P, Open-market purchase Exicure, Inc.XCUR 500,000, acquired Open Form 4 filing 0001698530-19-000111
2019-01-18 P, Open-market purchase Alpine Immune Sciences, Inc.ALPN 1,024,999, acquired Open Form 4 filing 0000899243-19-001661
2017-09-26 P, Open-market purchase Max-1 Acquisition CorpXCUR 199,998, acquired Open Form 4 filing 0000899243-17-022826
2014-09-23 P, Open-market purchase Oncothyreon Inc.ONTY 500,000, acquired Open Form 4 filing 0001209191-14-059877
2012-06-29 S, Open-market sale Access Pharmaceuticals IncACCP 99,074, disposed Open Form 4 filing 0001140361-12-031724
2012-06-28 S, Open-market sale Access Pharmaceuticals IncACCP 16,875, disposed Open Form 4 filing 0001140361-12-031724
2012-05-16 S, Open-market sale Access Pharmaceuticals IncACCP 94,001, disposed Open Form 4 filing 0001140361-12-025869
2012-05-15 S, Open-market sale Access Pharmaceuticals IncACCP 850, disposed Open Form 4 filing 0001140361-12-025869
2007-10-15 P, Open-market purchase Targanta Therapeutics Corp.TARG 5,750,000, acquired Open Form 4 filing 0001181431-07-062699

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
D, Director
Director
O, Officer
Officer

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 15
  • Open-market sale 3
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Venkatesan Jay, insider transactions. Retrieved 2026-08-25 from https://ebomi.com/insider/0001413350

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.